Effect of EphA2 Silencing on Inhibiting the Progression of Renal Cell Carcinoma in an Orthotopic Mouse Model
Cells · 2025
DOI: 10.3390/cells14241981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Taein Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of …. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Receptor, EphA2, Disease Progression. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University Hospital, Seoul National University Hospital Research Fund.
Abstract (Originalsprache)
Background
We investigated whether EphA2 inhibition can attenuate the progression of renal cell carcinoma (RCC) in an orthotopic mouse model of kidney tumor cells (Renca). Materials and Methods: 16 BALB/c mice were divided into two groups and implanted with either control or shRNA-mediated, EphA2-knockdown Renca–Luciferase cells via injection under the right renal capsule. Tumor progression was followed by in vivo bioluminescence imaging (BLI). Tumor growth was evaluated via ex vivo BLI and the wet weight of harvested orthotopic kidneys on day 18. Tumor apoptosis was evaluated using the TUNEL assay. Changes in FAK/RhoA signaling, a mediator of malignant cellular behavior, were determined using Western blotting and RT-PCR.
Results
The TUNEL assay showed increased apoptosis of tumor cells in the EphA2-knockdown group compared to that in the control group (p = 0.021). Tumor wet weight (1569.9 ± 595.5 vs. 636.5 ± 288.9 mg, p = 0.009) and activation of RhoA and FAK were decreased in the EphA2-knockdown group (p < 0.05 for all). Tumor burden was reduced in the EphA2-knockdown group according to in vivo BLI on days 14 and 18 and an ex vivo test (p = 0.021, p = 0.043, p = 0.021).
Conclusions
EphA2 knockdown significantly reduced the progression of RCC by inducing tumor apoptosis and suppressing FAK/RhoA signaling in an orthotopic mouse model. The EphA2/FAK/RhoA pathway might constitute a potential target to suppress the progression of RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of Korea.
- Department of Urology, Seoul National University Hospital, Seoul 03080, Republic of Korea.
ORCID-Profile: Min Chul Cho
Förderung
- Seoul National University Hospital
- Seoul National University Hospital Research Fund
Zitieren
APA
Lee, T., Lee, H. S., Yoo, S., Bae, H., Cho, M. C., Lee, J., & Jeong, H. (2025). Effect of EphA2 Silencing on Inhibiting the Progression of Renal Cell Carcinoma in an Orthotopic Mouse Model. Cells. https://doi.org/10.3390/cells14241981
Vancouver
Lee T, Lee HS, Yoo S, Bae H, Cho MC, Lee J, et al. Effect of EphA2 Silencing on Inhibiting the Progression of Renal Cell Carcinoma in an Orthotopic Mouse Model. Cells. 2025. doi:10.3390/cells14241981
BibTeX
@article{Lee2025,
author = {Lee, Taein and Lee, Hye-Sun and Yoo, Sangjun and Bae, Hoyoung and Cho, Min Chul and Lee, Junghoon and Jeong, Hyeon},
title = {Effect of EphA2 Silencing on Inhibiting the Progression of Renal Cell Carcinoma in an Orthotopic Mouse Model},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14241981}
}
EUVIMED